Holoprosencephaly 4 (HPE4) Cell Models for Research

Holoprosencephaly (HPE) is a rare congenital brain malformation with an estimated prevalence of 1 in 250 conceptions, but only 1 in 10,000 live births due to high fetal mortality (WHO, 2023). HPE4 is a genetic subtype caused by mutations in the SHH gene, accounting for approximately 3-5% of all HPE cases. The clinical spectrum ranges from severe alobar HPE, often fatal in utero, to milder microforms with facial dysmorphism and normal intelligence. Survivors face significant neurological deficits, including intellectual disability, seizures, and endocrine dysfunction. The NCI does not track HPE4 as it is not a cancer, but the genetic pathways involved are relevant to cancer research. The 5-year survival for severe forms is low, but for milder forms, life expectancy may be near normal with appropriate management.

HPE4 serves as an ideal model for studying the SHH signaling pathway, which is critical in development and cancer. The disease is monogenic in many cases, allowing for clear genotype-phenotype correlations. Public datasets such as ClinVar and gnomAD provide variant information. Open questions include the role of modifier genes and the molecular mechanisms underlying variable expressivity. Gene-edited cell models enable functional validation of SHH mutations and exploration of pathway interactions.

• • While HPE4 is not a cancer, the SHH pathway is oncogenic when aberrantly activated. The pathway involves:

1. SHH ligand binding to PTCH1 receptor.

2. Relief of SMO inhibition.

3. Activation of GLI transcription factors.

4. Target gene expression (e.g., GLI1, PTCH1, MYC).

• • In HPE4, loss-of-function mutations in SHH reduce pathway activity, leading to developmental defects. Conversely, in cancer, activating mutations or overexpression of SHH can drive tumor growth.

| Gene | Frequency (%) | Mutation Type | Functional Effect |

|------|---------------|---------------|-------------------|

| SHH | 3-5% in HPE | Missense, nonsense, frameshift | Loss of function, reduced SHH signaling |

| SIX3 | 1-2% | Missense, deletions | Impaired forebrain development |

| TGIF1 | 1% | Missense | Disrupted TGF-β signaling |

| ZIC2 | 3-5% | Frameshift, nonsense | Loss of function, impaired neural development |

Data from ClinVar and COSMIC (for cancer-related mutations).

• • Key signaling networks in HPE4 include:
• • SHH signaling: SHH, PTCH1, SMO, GLI1-3.
• • TGF-β signaling: TGIF1, SMADs.
• • Wnt signaling: interactions with SHH in forebrain patterning.
• • Notch signaling: cross-talk with SHH in neural stem cells.
• • These networks are critical for cell proliferation and differentiation. In gene-edited models, disruption of SHH can be studied in isolation.

| Cell Line | Origin | Key Mutations |

|-----------|--------|---------------|

| SH-SY5Y | Neuroblastoma | SHH wild-type, but can be edited |

| HEK293 | Embryonic kidney | SHH wild-type, used for overexpression |

| iPSC-derived neural progenitors | Induced pluripotent stem cells | Patient-specific mutations |

Organoids derived from iPSCs can recapitulate forebrain development and are valuable for studying HPE4.

• • GEMM: Shh knockout mice show HPE-like phenotypes.
• • PDX: Not applicable for HPE4 as it is not a tumor.
• • Induced models: CRISPR-engineered mice with SHH mutations.
• • Zebrafish: Used for rapid functional analysis of SHH variants.

• • CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific SHH mutations. For example:
• • SHH knockout cell lines: complete loss of function.
• • SHH point mutation knock-in lines: mimic patient-specific missense mutations.
• • These models are sequence-verified and commercially available from various sources. They allow precise study of mutation effects on signaling and can be used for drug screening.

Knockout and knock-in lines are used to validate the functional impact of SHH mutations. For example, a SHH knockout cell line can be used to study downstream effects on GLI target genes. Knock-in lines with specific mutations can reveal genotype-phenotype correlations.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput screening of compounds that modulate SHH signaling. Resistance mechanisms can be studied by exposing cells to SMO inhibitors and selecting for resistant clones.

CRISPR synthetic lethality screens can identify genes that are essential in SHH-mutant cells but not in wild-type cells, providing potential therapeutic targets. Gene-edited cells can also be used to identify biomarkers for patient stratification.